Algert Global LLC Purchases New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Algert Global LLC bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,964 shares of the specialty pharmaceutical company’s stock, valued at approximately $637,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the last quarter. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after acquiring an additional 99,705 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 40.7% during the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after acquiring an additional 527,187 shares in the last quarter. Capital World Investors bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $171,943,000. Finally, Baupost Group LLC MA grew its stake in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $109.38 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.38. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The company has a market cap of $6.90 billion, a PE ratio of 22.55, a P/E/G ratio of 1.36 and a beta of 0.57. The stock has a 50 day simple moving average of $111.02 and a 200-day simple moving average of $110.39.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. On average, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on JAZZ. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Royal Bank of Canada raised their price objective on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the stock an “outperform” rating in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.14.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.